A Phase II study of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma: A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program Trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 242-246

  Vaughn, David J ^a,b   Meropol, Neal J ^c   Holroyde, Christopher ^b   Mintzer, David ^b   Nuamah, Isaac ^a   Armstead, Barbara ^b   Douglass Jr , Harold O ^c   Haller, Daniel G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Biochemical modulation; Chemotherapy; Gastric carcinoma; Gastroesophageal junction carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METASTASIS; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031005331     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00006     Document Type: Article

References (22)

1. Whelan SL, Parkin DM, Masuyer E, eds. Trends in cancer incidence and mortality. Lyon, France: IARG Scientific Publications, 1993.
2. Craanen ME, Dekker W, Blok P, et al. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992;87:572-9.
3. American Cancer Society. Cancer facts and figures 1995. Atlanta: American Cancer Society, 1995.
4. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
5. Havlin KA, Macdonald JS. Gastric cancer: chemotherapy of advanced disease. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal oncology. Philadelphia: JB Lippincott Company, 1992:171-80.
6. Reed E. Platinum analogues. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: the principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott Company, 1993:390-400.
7. Chabner BA, Myers CE. Antitumor antibiotics. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: the principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott Company, 1993:374-84.
8. Moertel CG, Rubin J, O'Connell MJ, et al. A Phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced gastrointestinal adenocarcmoma. J Clin Oncol 1986;4:1053-7.
9. Gohmann JJ, MacDonald JS. Chemotherapy of gastric cancer. Cancer Invest 1989;7:39-52.
10. Einhorn LH. Improvements in fluorouracil chemotherapy? J Clin Oncol 1989;10:1377-9.
11. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal cancer. J Clin Oncol 1989;7:890-9.
12. Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469-75.
13. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colon cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
14. Madajewicz S, Petrelli N, Rustrum YM, et al. Phase I-II trial of high dose calcium leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Cancer Res 1984;44:4667-9.
15. Vaughn DJ, Meropol NJ, Armstead B, et al. A pilot trial of 5-FU, leucovorin, and cisplatin with or without adriamycm in advanced cancer. AmJ Clin Oncol 1996:241-4.
16. Klein H, Wickremanayake P, Farrokh LG. 5-FU, adriamycin, and methotrexate: a combination protocol (FAMTX) for treatment of metastatic stomach cancer. Proc Am Soc Clin Oncol 1986;5:84.
17. Wils J, Bleiberg H, Daleiso O, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986;4:1799-803.
18. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
19. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
20. Einzig AL, Lipsitz S, Wiernik PH, et al. Phase II trial of taxotere in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) previously untreated with chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 1995;14:191.
21. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;14:1086-91.
22. Meropol NJ, Creavan PJ, Petrelli NJ. Metastatic colon cancer: advances in biochemical modulation and new drug development. Semin Oncol 1995;22:509-24.